Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001) (Q35703129)

From Wikidata

Jump to navigation Jump to search

scientific article published on 18 June 2014

Language	Label	Description	Also known as
English	Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001)	scientific article published on 18 June 2014

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24939212%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001) (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24939212%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

phase II clinical trial

0 references

1 reference

ChEBI release 2020-05-28

vatalanib succinate

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

pancreatic adenocarcinoma

1 reference

based on heuristic

inferred from title

metastatic pancreatic adenocarcinoma

1 reference

based on heuristic

inferred from title

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24939212%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

author name string

T Dragovich

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24939212%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

D Laheru

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24939212%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

F Dayyani

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24939212%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

V Bolejack

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24939212%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

L Smith

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24939212%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

J Seng

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24939212%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

H Burris

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24939212%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

P Rosen

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24939212%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

P Ritch

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24939212%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

A F Baker

11

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24939212%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

N Raghunand

12

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24939212%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

J Crowley

13

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24939212%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

D D Von Hoff

14

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24939212%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

publication date

18 June 2014

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24939212%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24939212%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

74

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24939212%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24939212%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

379-387

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24939212%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Pancreatic cancer clinical trials and accrual in the United States

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461053

27 July 2018

Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461053

27 July 2018

Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461053

27 July 2018

Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461053

27 July 2018

Pancreatic surgery for adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461053

27 July 2018

Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461053

27 July 2018

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461053

27 July 2018

Automated registration of sequential breath-hold dynamic contrast-enhanced MR images: a comparison of three techniques

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461053

27 July 2018

Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461053

27 July 2018

Management strategies in pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461053

27 July 2018

A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous dosing schedule in patients with advanced cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461053

27 July 2018

Angiogenesis: an update and potential drug approaches (review).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461053

27 July 2018

Biomarkers of response and resistance to antiangiogenic therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461053

27 July 2018

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461053

27 July 2018

Targeting angiogenesis in pancreatic cancer: rationale and pitfalls

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461053

27 July 2018

Pancreatic cancer microenvironment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461053

27 July 2018

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461053

27 July 2018

Hypoxia and angiogenesis in pancreatic cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461053

27 July 2018

Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461053

27 July 2018

Modeling tracer kinetics in dynamic Gd-DTPA MR imaging

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461053

27 July 2018

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2499-4

21 January 2018

New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2499-4

21 January 2018

Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2499-4

21 January 2018

Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2499-4

21 January 2018

Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2499-4

21 January 2018

Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer a

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2499-4

21 January 2018

Evaluation of lymph nodes with RECIST 1.1.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2499-4

21 January 2018

Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2499-4

21 January 2018

Impact of single centre status on estimates of intervention effects in trials with continuous outcomes: meta-epidemiological study

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2499-4

21 January 2018

Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2499-4

21 January 2018

Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2499-4

21 January 2018

Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2499-4

21 January 2018

Genome sequencing identifies a basis for everolimus sensitivity

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2499-4

21 January 2018

New developments in the treatment of pancreatic cancer. Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30 - June 3, 2008.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461053

25 September 2018

Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461053

25 September 2018

Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24939212

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00280-014-2499-4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24939212%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24939212%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24939212%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35703129&oldid=2197641753"